← United States · All US Insider Profiles

US INSIDER PROFILE · NON-SCORING RESEARCH

Bitterman Robert J

Chief Executive Officer

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001304395

Purchase history

Companies traded
1
Purchases · 12M
7
Purchases · 24M
10
Average purchase
$6.1K
Median purchase
$5.4K
Gross purchase value
$61.3K

Companies: Phio Pharmaceuticals Corp.

10 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

PublishedCompanyTickerRoleReported valueSEC source
2026-09-23Phio Pharmaceuticals Corp.PHIOChief Executive Officer$2.1KOpen filing
2026-08-19Phio Pharmaceuticals Corp.PHIOChief Executive Officer$10.6KOpen filing
2026-06-29Phio Pharmaceuticals Corp.PHIOChief Executive Officer$9.9KOpen filing
2026-01-02Phio Pharmaceuticals Corp.PHIOChief Executive Officer$5.2KOpen filing
2025-12-29Phio Pharmaceuticals Corp.PHIOChief Executive Officer$5.1KOpen filing
2025-11-24Phio Pharmaceuticals Corp.PHIOChief Executive Officer$5.7KOpen filing
2025-11-19Phio Pharmaceuticals Corp.PHIOChief Executive Officer$6.3KOpen filing
2025-06-11Phio Pharmaceuticals Corp.PHIOChief Executive Officer$4.8KOpen filing
2025-06-10Phio Pharmaceuticals Corp.PHIOChief Executive Officer$4.1KOpen filing
2025-05-23Phio Pharmaceuticals Corp.PHIOChief Executive Officer$7.4KOpen filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

No completed point-in-time price outcome is available yet.

Research patterns

First purchase in 12M
0/9
Large purchase ≥ $100k
0/10
Cluster buying · 15D
3/10
Buying the dip
0/—

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.